Crossref


3. Cost-Effectiveness Analysis of Adding Low Dose Ribavirin to Peginterferon Alfa-2a for Treatment of Chronic Hepatitis C Infected Thalassemia Major Patients in Iran

- Alireza Mehrazmay

- Seyed-Moayed Alavian

- Maziar Moradi-Lakeh

- Mahdi Mokhtari Payam

- Amir Hashemi-Meshkini

- Bita Behnava

- Seyyed Mohammad Miri

- Pegah Karimi Elizeh

- Seyed Vahid Tabatabaee

- Maryam Keshvari

- Kamran Bagheri Lankarani

6. Burden of Hepatitis C on Patients with Thalassemia

- Zahra Sepehri

- Seyed Moayed Alavian

7. Burden of Hepatitis C on Patients with Thalassemia

- Zahra Sepehri

- Seyed Moayed Alavian

8. The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C

- Bita Behnava

- Heidar Sharafi

- Maryam Keshvari

- Ali Pouryasin

- Leila Mehrnoush

- Shima Salimi

- Pegah Karimi Elizee

- Mehran Ghazimoghaddam

- Seyed Moayed Alavian

9. Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India

- Pankaj Puri

- Anil C. Anand

- Vivek A. Saraswat

- Subrat K. Acharya

- Shiv K. Sarin

- Radha K. Dhiman

- Rakesh Aggarwal

- Shivaram P. Singh

- Deepak Amarapurkar

- Anil Arora

- Mohinish Chhabra

- Kamal Chetri

- Gourdas Choudhuri

- Vinod K. Dixit

- Ajay Duseja

- Ajay K. Jain

- Dharmesh Kapoor

- Premashis Kar

- Abraham Koshy

- Ashish Kumar

- Kaushal Madan

- Sri P. Misra

- Mohan V.G. Prasad

- Aabha Nagral

- Amarendra S. Puri

- R. Jeyamani

- Sanjiv Saigal

- Samir Shah

- Praveen K. Sharma

- Ajit Sood

- Sandeep Thareja

- Manav Wadhawan

10. WITHDRAWN: Efficacy and Side Effects of Sofosbuvir and Daclatasvir for Treatment of Hepatitis C in Thalassemia Major Patients with Treatment Experience of Interferon-Based Regimens

- Jamshid Vafaeimanesh

- Fahimeh Safarnezhad Tameshkel

- Hossein Ajdarkosh

- Azita Azarkeyvani

- Mahmoodreza Khoonsari

- Amirhossein Faraji

- Masoudreza Sohrabi

- Sima Aten

- Hossein Keyvani

- Farhad Zamani

12. Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy

- Saleh Sandoughdaran

- Seyed Moayed Alavian

- Heidar Sharafi

- Bita Behnava

- Shima Salimi

- Leila Mehrnoush

- Maryam Keshvari

13. The Effectiveness of Sofosbuvir and Daclatasvir in the Treatment of Hepatitis C in Thalassaemia Major Patients and their Effect on Haematological Factors

- Farhad Zamani

- Hossein Ajdarkosh

- Fahimeh Safarnezhad-Tameshkel

- Azita Azarkeivan

- Hossein Keyvani

- Farshad Naserifar

- Jamshid Vafaeimanesh

14. Long-Term Follow-Up of Thalassemia Major Patients with Hepatitis C Virus Treated with Sofosbuvir and Daclatasvir: A Cohort Study

- Fahimeh Safarnezhad Tameshkel

- Mohammad Hadi Karbalaie Niya

- Bahareh Amirkalali

- Nima Motamed

- Jamshid Vafaeimanesh

- Mansooreh Maadi

- Masodreza Sohrabi

- Amir Hossein Faraji

- Mahmoodreza Khoonsari

- Hossein Ajdarkosh

- Mehdi Nikkhah

- Elham Sobh Rakhashankhah

- Farhad Zamani

16. The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C

- Po-Cheng Liang

- Pei-Chin Lin

- Ching-I. Huang

- Chung-Feng Huang

- Ming-Lun Yeh

- Yu-Sheng Zeng

- Wan-Yi Hsu

- Ming-Yen Hsieh

- Zu-Yau Lin

- Shinn-Cherng Chen

- Jee-Fu Huang

- Chia-Yen Dai

- Wan-Long Chuang

- Shyh-Shin Chiou

- Ming-Lung Yu

17. Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals

- Khashayar Hesamizadeh

- Heidar Sharafi

- Mohammad Saeid Rezaee-Zavareh

- Bita Behnava

- Seyed Moayed Alavian